Laurent Cany

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer

Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson et al. · Journal of Clinical Oncology · 2012 · 424 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

X. Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology · 2013 · 338 citations

Medicine, Oncology, Breast Oncology +14

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy

Stéphanie Hoppe, M. Rainfray, Marianne Fonck et al. · Journal of Clinical Oncology · 2013 · 231 citations

Medicine, Geriatric Medicine, Oncology +17